Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

No carcinogenicity study is required.

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

The available data give no concern on carcinogenic properties of the test substance. Thus, classification of Bis-(2-ethylhexyl)carbonate as carcinogenic is not required according to Directive 67/548/EEC as well as GHS Regulation EC No 1272/2008 and therefore labelling is not necessary.

Additional information

No carcinogenicity study is required. The mutagenic and clastogenic potential of Bis(2-ethylhexyl) carbonate has been evaluated in the full range of in vitro studies and in a single in vivo genotoxicity study. There was no evidence for genotoxic properties of Bis(2-ethylhexyl) carbonate. Available data on repeated dose toxicity give no concern on carcinogenic properties of the substance. Although carcinogenicity studies are not available for Bis(2-ethylhexyl) carbonate, available data on genotoxicity and repeated dose toxicity do not raise any specific concerns with regard to carcinogenicity.

Carcinogenicity in humans is not expected.


Justification for selection of carcinogenicity via oral route endpoint:
No carcinogenicity study is required.. Available data give no concern on carcinogenic properties of the substance.